Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine nasal spray versus quetiapine XR augmentation in treatment-resistant major depressive disorder
NL-OMON55043Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in major depressive disorder (MDD) comparing Esketamine arm with Quetiapine XR comparator arm (2 arms). Primary endpoint: Primary: remission at Week 8. Started Oct 2021; status: completed.
02
Drugs
esketaminequetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON55043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55043.